Illumina, Inc. has grown revenue 0.24% a year over three years and 2.5% a year over five. Revenue growth, 3-year annual rate: +0.24% (Diagnostics & Research median +8.4%). Revenue growth, 5-year rate: +2.5%, growth has slowed since the five-year average. Years of annual history on file: 18, FY2008 to FY2025, as filed.

ILMNIllumina, Inc.

Healthcare

$278.10+171% 1Y

$278.10

$91.0052 weeks$293.84

Is it growing?

Watch

Growth is fading: earnings down −32% year on year and operating margin narrowing (−10.5 points).

2 to watch, 1 neutral

Revenue trend+5% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +3% a year.

Earnings trend−32% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction−10.5 points operating

Trailing-twelve-month operating margin, 19.6% now against 30.1% a year earlier.

All from SEC EDGAR, as of Jun 28, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearsbehind 77% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is ILMN growing?

Illumina, Inc. has grown revenue 0.24% a year over three years and 2.5% a year over five.

+0.24%

Revenue growth, 3-year annual rate · Diagnostics & Research median +8.4% · growing slowly · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +2.5%
Revenue growth, 5-year rate · +0.24% over three · growth has slowed since the five-year average
Years of annual history on file: 18
Years of annual history on file · FY2008 to FY2025, as filed

Details›